Dyax' HAE drug gets nod from FDA panel

Dyax' investigational hereditary angioedema drug ecallantide has been recommended for approval by a US Food and Drug Administration  expert panel. The agent, which has the proposed brand name of Kalbitor,  is Cambridge, Massachusetts, USA-based Dyax' lead product candidate. The  FDA's Pulmonary-Allergy Advisory Committee voted six to five with two  abstentions in favor of approving the agent for the treatment of acute  attacks of HAE, which is a rare, potentially-fatal genetic disorder  characterized by spontaneous swelling. The FDA usually follows the  advice of its Committees. A final decision is expected by March 23.